Evidence map›Paper›PMID 33616800›Full record

ReviewReviews in endocrine & metabolic disorders2021

Cardiovascular risk and testosterone - from subclinical atherosclerosis to lipoprotein function to heart failure.

Baris Gencer, Marco Bonomi, Maria Pia Adorni, Cesare R Sirtori, François Mach, Massimiliano Ruscica

Open access · hybridAbstract readReview
In one paragraph

Review in Reviews in endocrine & metabolic disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
14.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Sleep apnea pathophysiology.Sleep & breathing = Schlaf & Atmung · 2023
    Review
  11. Article
  12. Review
  13. The Role of High-Density Lipoprotein Cholesterol in 2022.Current atherosclerosis reports · 2022
    Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Baris GencerCardiology Division, Geneva University Hospitals, Geneva, Switzerland. baris.gencer@hcuge.ch.
Marco BonomiDepartment of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milan, Italy.ORCID 0000-0001-5454-6074
Maria Pia AdorniDepartment of Medicine and Surgery-Unit of Neurosciences, University of Parma, Parma, Italy.
Cesare R SirtoriDepartment of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy.
François MachCardiology Division, Geneva University Hospitals, Geneva, Switzerland.
Massimiliano RuscicaDepartment of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy. massimiliano.ruscica@unimi.it.ORCID 0000-0002-0195-7061
University of Milan · ITUniversity Hospital of Geneva · CHUniversity of Geneva · CHUniversity of Parma · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cardiovascular (CV) benefit and safety of treating low testosterone conditions is a matter of debate. Although testosterone deficiency has been linked to a rise in major adverse CV events, most of the studies on testosterone replacement therapy were not designed to assess CV risk and thus excluded men with advanced heart failure or recent history of myocardial infarction or stroke. Besides considering observational, interventional and prospective studies, this review article evaluates the impact of testosterone on atherosclerosis process, including lipoprotein functionality, progression of carotid intima media thickness, inflammation, coagulation and thromboembolism, quantification of plaque volume and vascular calcification. Until adequately powered studies evaluating testosterone effects in hypogonadal men at increased CV risk are available (TRAVERSE trial), clinicians should ponder the use of testosterone in men with atherosclerotic cardiovascular disease and discuss benefit and harms with the patients.

Indexed as

AtherosclerosisCardiovascular DiseasesHeart FailureCarotid Intima-Media ThicknessHeart Disease Risk FactorsHumansLipoproteinsMaleProspective StudiesRisk FactorsTestosteroneLipoproteinsTestosteroneAtherosclerosisCardiovascular riskCholesterol-efflux capacityHypogonadismInflammationTestosterone

Identifiers

PMID33616800
PMCPMC8087565
OpenAlexW3131770408

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.